U.S. Professional Services Stock News

Lumen Technologies (LUMN) FY 2025 earnings snapshot Lumen Technologies (LUMN) closed FY 2025 with fourth quarter revenue of US$3.0 billion and basic EPS of roughly US$0.00, as net income excluding extra items landed at a loss of US$2 million. The company has seen quarterly revenue move from US$3.3 billion and basic EPS of US$0.09 in Q4 2024 to US$3.0 billion and a near breakeven basic EPS in Q4 2025, alongside a trailing twelve month loss of US$1.7 billion on basic EPS of US$1.75. With...

If you are wondering whether Parker-Hannifin shares around US$967.62 still offer value after a strong run, you are not alone. That is exactly what this article will unpack for you. The stock has returned 2.0% over the last 7 days, 4.2% over 30 days, 8.2% year to date, 41.3% over 1 year, 184.3% over 3 years and 277.7% over 5 years, which naturally raises questions about how much of the story is already reflected in the price. Recent attention on Parker-Hannifin has centered on its position in...

If you are wondering whether Olin is attractively priced at its current share price, this breakdown will help you see how the market is valuing the business today. The stock recently closed at US$23.41, with returns of 4.8% over the last 7 days, 4.9% over the last 30 days, 8.6% year to date, but a 14.8% decline over 1 year and a 58.3% decline over 3 years, while the 5 year return stands at a 10.5% decline. Recent news coverage has focused on Olin's position within the materials sector and...

Why U.S. Physical Therapy Is Drawing Fresh Attention U.S. Physical Therapy (USPH) is back on investor radars after a recent share price move, with the stock up around 3% over the past month and roughly 14% in the past 3 months. See our latest analysis for U.S. Physical Therapy. That recent 3 month share price return of 13.81% sits against a one year total shareholder return decline of 1.89% and a 5 year total shareholder return decline of 33.30%, which suggests near term momentum has picked...

Polaryx Therapeutics (PLYX) has drawn investor attention after a sharp 28.9% single day share price decline, with the stock closing at US$16. This move comes against a year to date return of negative 54.3%. See our latest analysis for Polaryx Therapeutics. The sharp 28.9% single day share price return decline and the year to date share price return of 54.3% point to fading momentum, suggesting that recent moves reflect shifting risk perception more than steady longer term sentiment. If...

Park Hotels & Resorts recently drew attention as major brokerages issued mixed ratings ahead of its upcoming Q4 and full-year 2025 results, while the company continued reshaping its portfolio and refinancing debt maturities with US$2.00 billion in credit facilities. This flurry of analyst views, combined with Park’s shift toward higher-quality domestic assets and efforts to address near-term debt, highlights how governance, balance sheet management, and asset quality are becoming central to...

AtriCure (ATRC) has drawn investor attention after a period of mixed share performance, with a loss of 9.18% over the past month but a 16.83% gain in the past 3 months. See our latest analysis for AtriCure. At a share price of $36.80, AtriCure’s recent 7 day and 1 month share price returns of 2.57% and 9.18% declines contrast with a 16.83% gain over 90 days. The 1 year, 3 year and 5 year total shareholder returns of 10.96%, 13.92% and 41.49% declines indicate that momentum has only recently...

If you are trying to figure out whether Waystar Holding stock now offers value, it helps to step back from the recent share price swings and look at what the current market price might be implying. Over the recent period, the shares closed at US$23.99, with returns of a 13.1% decline over 7 days, a 24.5% decline over 30 days, a 23.5% decline year to date, and a 42.8% decline over 1 year, which may prompt questions about how risk and potential reward are being priced in. These moves sit...

Truist Financial (NYSE:TFC) has launched an AI powered integrated receivables platform for commercial and corporate clients. The new platform uses machine learning tools to support cash management, operational efficiency, and fraud controls. The offering targets long standing receivables and payments pain points for finance teams across Truist’s business client base. For investors watching Truist Financial at a share price of $55.14, this move sits alongside a period of positive stock...

Quaker Chemical (KWR) drew fresh attention after its recent earnings modestly topped expectations, with management pointing to strong customer demand, realized synergies, and greater use of higher-value formulations as key drivers. See our latest analysis for Quaker Chemical. The recent earnings beat has been followed by strong momentum in the share price, with a 1-month share price return of 20.28% and a 90-day share price return of 29.22%. The 1-year total shareholder return of 26.60%...

Darden Restaurants (NYSE:DRI) is discontinuing the Bahama Breeze brand and closing 14 locations. Roughly half of the remaining Bahama Breeze sites will be converted to other Darden concepts. The move is part of a broader portfolio reshaping focused on brands with stronger unit economics. Darden Restaurants, trading at $212.22, is acting on a full review of its brand portfolio by winding down Bahama Breeze and reallocating those locations to concepts it views as more scalable. The stock has...

Weatherford International’s FY 2025 Earnings Snapshot Weatherford International (WFRD) closed out FY 2025 with Q4 revenue of US$1.3b and basic EPS of US$1.92, backed by net income of US$138m. The company has seen quarterly revenue range from US$1,193m to US$1,341m across the last six reported periods, while basic EPS has moved between US$1.04 and US$2.14 over the same stretch. This provides a clear view of how the top and bottom lines have tracked through the cycle. With a trailing twelve...

In January 2026, Cogent Biosciences announced that the FDA granted Breakthrough Therapy Designation to bezuclastinib plus sunitinib for previously imatinib-treated GIST, based on PEAK trial data showing improved progression-free survival and a favorable safety profile compared with sunitinib alone. The FDA’s decision to review Cogent’s New Drug Application under its Real-Time Oncology Review program highlights regulatory interest in potentially accelerating access to this combination...

Graco (GGG) is back in focus after its fourth quarter and full year 2025 earnings, where sales, net income, and earnings per share all came in higher than the prior year’s levels. See our latest analysis for Graco. The earnings release and 2026 sales guidance have come alongside a 1-day share price return of 3.14%, adding to a 30-day share price return of 9.66% and a 1-year total shareholder return of 9.69%. Taken together, these figures suggest that momentum has been picking up recently. If...

Clinical and financing moves put Sangamo Therapeutics (SGMO) in focus Sangamo Therapeutics (SGMO) moved into the spotlight after releasing detailed Phase 1/2 STAAR study data for its Fabry gene therapy candidate, alongside a US$25 million follow on equity offering and a change in its finance leadership. See our latest analysis for Sangamo Therapeutics. Against this backdrop of clinical data, financing and leadership change, Sangamo Therapeutics’ share price has been under pressure, with a 30...

Warby Parker recently highlighted its resilience in a softer consumer backdrop, supported by a broader in-network insurance footprint that now includes Versant and helps capture demand as customers use their vision benefits, particularly in the seasonally important fourth quarter. At the same time, the company is positioning itself as an early mover in intelligent eyewear through partnerships with Google and Samsung, backed by substantial capital and product development support from these...

The spotlight on Starwood Property Trust (STWD) has sharpened as investors weigh its high dividend yield against interest rate and real estate cycle risks, while Starwood Capital refreshes U.S. asset management leadership with John Gonnella’s appointment. See our latest analysis for Starwood Property Trust. Despite the latest leadership move at Starwood Capital, Starwood Property Trust’s share price has been relatively steady, with a 2.21% 1 day share price return and a 1.15% 90 day share...

If you are wondering whether Danaher's current share price lines up with its underlying value, you are not alone. This article is designed to help you size that up with clear numbers. Over the past month, the stock has seen a 6.7% decline, with a 2.2% drop over the last week and a 4.7% decline year to date, while the 1 year return stands at 4.1% and the 5 year return at 6.6%. These moves sit against a backdrop of ongoing interest in Danaher as a large life sciences and diagnostics group,...

Emerson Electric (EMR) opened fiscal 2026 with Q1 revenue of US$4.3b and basic EPS of US$1.08, alongside net income from continuing operations of US$605m. This sets a clear benchmark for how the year is starting to shape up. The company has seen quarterly revenue move between US$4.2b and US$4.9b over the past year, while basic EPS ranged from about US$0.86 to US$1.12. This gives investors a consistent read on earnings power as they track the latest print. With trailing net margin at 12.7% and...

If you are wondering whether Boot Barn Holdings at around US$183 per share looks expensive or offers value, it helps to step back and look at what the current price actually builds in. The stock has moved around recently, with a 6.3% gain over the last week, a 5.3% decline over the last month, and a year to date return of a 1.8% decline. The one year return sits at 27.2%, the three year return is 120.4%, and the five year return is 205.2%. These swings have put valuation back in focus for...

Coty (NYSE:COTY) has entered a partnership with OpenAI to roll out artificial intelligence tools across its global operations. The company has also released a limited edition Bridgerton inspired fragrance collection in collaboration with Netflix and Shondaland. These moves highlight Coty's push to update its technology stack while testing fresh branded product concepts in the fragrance segment. Coty comes into these announcements with a current share price of $3.43 and mixed recent...

Amcor (AMCR) has just posted Q2 2026 results with revenue of US$5.4b and net income of US$177m, equal to EPS of US$0.38, putting a fresh marker down for how the packaging group is currently earning its margins. The company has seen quarterly revenue move from US$3.2b in Q2 2025 through US$5.1b in Q4 2025 to US$5.7b in Q1 2026 and now US$5.4b, while EPS has ranged from US$0.56 in Q2 2025 to a small loss in Q4 2025 before landing at US$0.57 in Q1 2026 and US$0.38 this quarter. This sets up a...

TAL Education Group recently reported past third-quarter and nine-month 2025 results, with sales rising to US$770.17 million and US$2.21 billion respectively, alongside higher net income and earnings per share from continuing operations versus the prior year. The company also completed a share repurchase of 5,039,921 shares for US$162.4 million, modestly shrinking its share count while analyst earnings expectations have been revised higher. We’ll now look at how TAL’s strong earnings growth...

Wondering if Crown Castle is offering value at its current share price, or if it is a value trap? This article walks through what the numbers suggest without the hype. The stock last closed at US$86.11, with a 1.4% gain over the past week, a 2.6% decline over the last month, a 2.9% decline year to date, a 0.8% return over 1 year, a 29.2% decline over 3 years, and a 33.4% decline over 5 years. Recent attention on Crown Castle has been driven by ongoing interest in tower and infrastructure...